

An alternative host model of a mixed fungal infection by azole susceptible and resistant *Aspergillus* spp strains

L Alcazar-Fuoli, Mj Buitrago, A Gomez-Lopez & E Mellado

To cite this article: L Alcazar-Fuoli, Mj Buitrago, A Gomez-Lopez & E Mellado (2015) An alternative host model of a mixed fungal infection by azole susceptible and resistant *Aspergillus* spp strains, *Virulence*, 6:4, 376-384, DOI: [10.1080/21505594.2015.1025192](https://doi.org/10.1080/21505594.2015.1025192)

To link to this article: <https://doi.org/10.1080/21505594.2015.1025192>



© 2015 Taylor & Francis Group, LLC



Published online: 11 Jun 2015.



Submit your article to this journal [↗](#)



Article views: 309



View related articles [↗](#)



View Crossmark data [↗](#)



Citing articles: 5 View citing articles [↗](#)

An alternative host model of a mixed fungal infection by azole susceptible and resistant *Aspergillus* spp strains

L Alcazar-Fuoli, Mj Buitrago, A Gomez-Lopez, and E Mellado

Mycology Reference Laboratory; Centro Nacional de Microbiología; Instituto de Salud Carlos III; Madrid, Spain

Keywords: *Aspergillus* spp, *cyp51A*, *Galleria mellonella* infection model, mixed infection, one-step single tube real time PCR

Aspergillus fumigatus is the most common mold involved in human infections. However, the number of non-*fumigatus* species able to cause disease is continuously increasing. Among them, *Aspergillus lentulus* is reported in hematological and cystic fibrosis patients and in those treated with corticosteroids. *A. lentulus* differs from *A. fumigatus* in some clinically relevant aspects such as virulence and antifungal susceptibility, showing high MICs to most antifungals. Previous studies proved that *A. lentulus* was pathogenic in immunocompromised mice, although the course of the infection was delayed compared to *A. fumigatus*. These differences could explain why *A. lentulus* is mostly found in mixed infections with *A. fumigatus* challenging the diagnosis and treatment. We used the alternative model host *Galleria mellonella* to compare virulence, host interaction, fungal burden and antifungal response when larvae were infected with *A. fumigatus* or *A. lentulus* alone, and with a mixture of both species. *A. lentulus* was pathogenic in *G. mellonella* but infected larvae did not respond to therapeutic doses of voriconazole. We were able to simultaneously detect *A. fumigatus* and *A. lentulus* by a multiplex Nested Real Time PCR (MN-PCR). Comparative analysis of larvae histological sections showed melanization of both species but presented a different pattern of immune response by haemocytes. Analysis of fungal burden and histology showed that *A. lentulus* survived in the *G. mellonella* despite the antifungal treatment in single and mixed infections. We conclude that the simultaneous presence of antifungal susceptible and resistant *Aspergillus* species would likely complicate the management of these infections.

Introduction

The incidence of invasive fungal diseases (IFD) together with the number of fungal species pathogenic for humans has increased in the past decade.^{1–3} *Aspergillus fumigatus* continues to be the most common fungi isolated from *Aspergillus* related mycosis. However, the epidemiology of these infections is changing with new emerging cryptic species becoming isolated and occasionally causing disseminated infections in immunocompromised hosts.^{3,4} The risk factors associated with these cryptic species are still undefined but it is known that they show remarkable high MICs to multiple antifungal agents.^{5,6} The reasons for this change in fungal populations, as well as the emergence of drug resistance, are still poorly understood.

Aspergillus lentulus, one of these sibling species belonging to the section *Fumigati*, can be considered as an uncommon fungal pathogen for humans. However, it has been increasingly reported in severely immunocompromised patients such as hematological and cystic fibrosis patients, those suffering from chronic obstructive pulmonary disease (COPD) or other populations receiving high doses of corticosteroids.^{7–10} Invasive aspergillosis caused by *A. lentulus* is associated with high mortality and clinical isolates

of this species show high MICs to azoles, echinocandins and amphotericin B.^{6–9,11} Resistance to voriconazole (VRC) is especially worrisome considering that this antifungal is the primary drug used to treat invasive aspergillosis. *A. lentulus* cannot be distinguished by classical morphological methods from other *Fumigati* section species including *A. fumigatus*. To solve this problem, molecular methods based on amplification and sequencing of the β -tubulin, rodlet or calmodulin genes are currently used in order to differentiate them at species level. Colonies of *A. lentulus* appear to be less sporulated and are white colored compared to *A. fumigatus*. Pathogenicity of *A. lentulus* has been proven in immunocompromised mice although the course of infection was delayed compared to *A. fumigatus* when the same intranasally administered inocula size was used.¹² This difference in the developmental fungal growth in vivo might explain why *A. lentulus* is frequently isolated in mixed infections with *A. fumigatus* or other *Aspergillus* spp.^{7,9} The simultaneous co-infection by multiple fungal species could represent a possible threat as *A. lentulus* is often misidentified and shows resistance to most antifungals in clinical use. In addition, population dynamics on a fungal mixed infection and species interaction in the host and in the environment remains entirely unexplored.

To date, murine models are considered to be the gold standard to study fungal pathogenesis and analyze efficacy of antifungal treatment. However, economic and logistical factors, together with ethical considerations, are limiting the use of mammals in infection experiments. To overcome these limitations, an alternative approach using different invertebrate infection models has been developed, including amoebae, *Caenorhabditis elegans*, *Drosophila melanogaster*, and larvae of the wax moth *Galleria mellonella*.¹³ All of them are inexpensive, ethically approved and do not require specialized facilities for maintenance. Compared to other invertebrates, *G. mellonella* offers several advantages that include: the size of the larvae which facilitates easy handling; and the possibility of injecting a defined inoculum and drug concentration. Furthermore, in contrast to other invertebrate hosts, *G. mellonella* larvae can be maintained at temperatures up to 37°C, equivalent to the temperature in mammalian hosts.^{14,15}

In this study we first optimized a one-step diagnostic tool based on multiplex nested PCR (MN-PCR) for simultaneous detection of *A. fumigatus* and *A. lentulus* that allowed fungal quantification from tissue samples. We then established a host model of mixed infection with *A. fumigatus* and *A. lentulus* in the alternative host *G. mellonella*. The model was used to evaluate differences in virulence, fungal burden, pathogenesis and antifungal drug response in presence of *Aspergillus* species mixtures in vivo.

Material and Methods

Strains, media and growth conditions

For the standardization and validation of the one step multiplex nested-PCR (MN-PCR) a total of 20 clinical strains for each species (20 *A. fumigatus* and 20 *A. lentulus*) were employed. All strains belonged to the Mycology Reference Laboratory collection, except the strain AF14¹⁶ that was kindly donated by Dr. J.A. Calera. The specificity of the technique was assessed with other fungal species with clinical origin: *Aspergillus flavus* (CM-2669), *Aspergillus terreus* (CM-2013), *Fusarium verticillioides* (CM-2975), *Fusarium oxysporum* (CM-2914), *Scedosporium prolificans* (CM-1627), *Scedosporium apiospermum* (CM-3169), *Cryptococcus neoformans* (CL2132), *Rhizopus oryzae* (CM-3020), *Rhizomucor variabilis* (CM-2437), *Candida albicans* (ATCC64551) and *Candida glabrata* (CL5533). In addition, human and murine genomic DNAs (Promega, Madrid, Spain) were included.

A. fumigatus (*akuB*^{KU80}),¹⁷ CM-237,¹⁸ AF14¹⁶ and *A. lentulus* (CM-1290) strains were selected for our infection model and further analysis.

Fungal strains were routinely grown at 37°C on different media: GYEP (2% glucose, 0.3% yeast extract, 1% peptone), Sabouraud (2% glucose, 1% mycopeptone) and potato dextrose agar. Minimal media (MM) containing 5 mM ammonium tartrate, 1% (w/v) glucose, and 2% (v/v) salt solution was used for phenotypic testing.¹⁹

Radial growth was measured for 5 d by point inoculation of 5×10^4 spores of *A. fumigatus* and *A. lentulus* on MM, at 37°C. *Aspergillus* species susceptibility profiles to voriconazole⁶ was confirmed by E-test according to the manufacturer's instructions (TecLaim S.A).

DNA extraction

Genomic DNA from *Aspergillus* spp and other fungal strains were isolated using a rapid extraction procedure.²⁰ Two µL of extracted DNA were used for each PCR reaction. DNA extraction from lung tissue samples used to validate the PCR assay, was performed using the QiAmp DNA Kit (Qiagen, Izasa, Madrid, Spain) following manufacturer recommendations. Elution was performed in 50 µL of elution buffer. DNA from *G. mellonella* was isolated from 0.85 % saline homogenized larvae as follows: DNA from 25 mg of homogenized larvae was isolated using the QiAmp DNA Kit for tissues, following manufacturer's instructions and eluting in 50 µL. All samples were stored at -20°C and they were allowed to thaw at room temperature before testing.

Multiplex Nested-PCR assay

Primers and Probes design

Primers and molecular beacon probes were designed on the basis of the nucleotide sequence of the *cyp51A* gene from 10 strains of each *A. fumigatus* and *A. lentulus*. The Beacon Designer 7.0 software (Premier Biosoft, Palo Alto, CA) was employed to design primers and probes for the MN-PCR assay. Selected primers and probes were subjected to a blast search into the GenBank sequence database (<http://www.ncbi.nih.gov/Genbank/>) to avoid cross-homology with other organisms. The primers for the first PCR were designed with a primer-annealing temperature higher than the primers for the second PCR segment (Table 1).²¹ The first PCR segment at that temperature did not allow the primers for the second PCR to anneal to the template. The outer

Table 1. Primers and Probes Sequences designed for the Multiplex Nested Real Time PCR assay.

Primer Name	Sequence (5'-3') ^a
OliNestCyp51A1 (Forward. First PCR)	CTYGCTCAATGTYGTTTATCAAYATTCTTCYCGGC
OliNestCyp51A2 (Reverse. First PCR)	CGCMGACTGAGTYAAGCCGTACTTGATGAACCTC
OliCyp51int-3 (Forward, second PCR)	CAGAACCGCCAATGGTCT
OliCyp51int-2 (Reverse, second PCR)	GACRTCTTGAGCTTGCC
Cyp51int-AF (<i>A.fumigatus</i> probe)	FAM-CGCGATCAGATTGTAGTTTGACATTCATTCTGGGGATCGCG-BHQ1
Cyp51int-AL (<i>A.lentulus</i> probe)	HEX-CGCGATCAGCTAGCGTCTGACATTTATCCCGGATCGCG-BHQ1

^aUnderlining regions indicates the PCR target sequence

primers were degenerated to hybridize with all species belonging to the *Fumigati* section to be used in future assays. The Molecular Beacon probes were designed based on the species specific *cyp51A* intron sequences (Supplementary Fig. 1) and were labeled with 5' 6-carboxyfluorescein (FAM) for *A. fumigatus* and 4,7,2', 4', 5', 7'-hexachloro-6-carboxyfluorescein (HEX) for *A. lentulus* (Sigma-Genosys, Spain). Both were labeled with Black Hole Quencher1 (BHQ1) in the 3' end as quencher.

PCR conditions and standardization in vitro

PCR reactions were undertaken in a LC480 unit (Roche Diagnostics, Madrid, Spain). The SensiMix (dT) kit 2x (Bioline, Ecogen, Spain) was used following manufacturer's instructions. The PCR was performed in a total volume of 20 μ L. The PCR mixture contained 0,05 μ M each of the first-PCR primers, 0,5 μ M each of the second-PCR primers, 0,4 μ M of both probes, 3mM $MgCl_2$ and a 2 μ L aliquot of DNA from the extracted sample. Cycling conditions included a first step for pre-incubation (activation of the enzyme) and denaturation of the template DNA at 95°C during 10 minutes. The first PCR consisted on only 10 cycles which included 25s at 95°C, 30s at 58°C and 5s at 72°C. The first PCR was immediately followed by the second PCR: 40 cycles which included 25s at 95°C, 30s at 52°C and 5s at 72°C. Quantification standards were run in conjunction which each set of samples as well as negative controls.

Standard curves were constructed with PCR results from 5 repetitions of different dilutions of *A. fumigatus* (CM-237) and *A. lentulus* (CM-1290) genomic DNA. Dilutions ranged from 20 ng to 2 fg DNA/20 μ L of reaction. A regression line (Supplementary Fig. 2) was constructed by plotting the Log10 concentration of DNA vs. its corresponding threshold cycle value (Ct). If this curve exhibited a linear regression coefficient value of >0.980, the standard curve was then used to determine the efficiency of the PCR, sensitivity and reproducibility of the assay. In order to evaluate the specificity, 2 ng of DNA/20 μ L from the species mentioned before (see Control strains) as well as human and mouse genomic DNA were included in the PCR assay.

Data were analyzed using LC480 software (Roche Diagnostics, Madrid, Spain) and a color compensation experiment was created to avoid signal overlapping between both fluorophores. Each PCR run contained both positive and negative controls consisting of water and different concentrations of genomic DNA from *A. fumigatus* or *A. lentulus*.

Murine infections

Murine models for lung sample collection were performed according to the models previously described.^{22,23} Murine infections were performed in compliance with Real Decreto 223/1988 for the protection of experimental animals and the Project License CBA PA_02_2013. The experiments were carried out with 8 mice per group. Leukopenic and corticosteroid treated mice were infected by intranasal instillation of 10⁵ spores/mice conidia in 30 μ L of saline solution. Survival was monitored over a 14 day period, cages were checked twice daily and those mice that developed signs of severe respiratory distress and reduction in body weight were sacrificed. Control groups (not infected and

not immunosuppressed, and not infected but immunosuppressed) had no symptoms of infection and were sacrificed at the end of the experiment.

Whole lungs were collected and homogenized in saline. An aliquot of this homogenate was plated onto Sabouraud plus chloramphenicol and gentamicin for fungal infection validation. The rest of the homogenate was stored at -20°C until DNA extraction was performed.

Galleria mellonella survival assay

Wax-moth larvae were infected with *A. fumigatus* strain *akuB*^{KU80} or *A. lentulus* CM-1290, or both in the mixed infection experiments. Wax moth larvae killing assays were carried out as described previously.^{24,25} Briefly, groups of 10 larvae (0.3–0.5 g, Alcotan S.L., Valencia, Spain) were inoculated with 10 μ L of a 10⁷ conidia/ml suspension in PBS into the haemocoel, so the final inoculum in each group was 10⁵ conidia per larva. Mixed infected larvae were inoculated with *A. fumigatus* and *A. lentulus* (ratio 1:1) to a final concentration of 10⁵ conidia per larvae.

Within two hours of the infection, 5 μ L of voriconazole (VRC, Pfizer SA) antifungal solution (VRC: 400 μ g/ml) (2 μ g/larva equivalent to 10 mg/kg therapeutic dose of VRC) was injected into a different proleg using the same technique. After that, caterpillars were incubated at 37°C for 10 d. Mortality, defined by lack of movement in response to stimulation and melanization of the cuticle, was recorded daily. Control groups were included: untouched, pierced, PBS and antifungal toxicity. Each experiment was performed in duplicate at least 3 times and the results were reported as mean values. To simplify some of the Figures, PBS control, toxicity and untouched groups were omitted.

Histopathological analysis of infected *G. mellonella*

Larva histology was performed as described before.²⁶ Three larvae per group were longitudinally sectioned and fixed for 24 h in 4% buffered formalin and dehydrated with increasing concentrations of ethanol (70%, 80%, 90%, 96% and 100%). The samples were then treated with xylene and paraffin embedded. Tissue sections of 5 microns were stained with periodic acid Schiff (PAS) and sections examined with a Leica DMI 3000B microscope.

Fungal burden quantification in *G. mellonella*

In order to assess fungal burden as a quantitative criterion for virulence and antifungal response, the MN-PCR assay described before was performed on total genomic DNA extracted from homogenized *G. mellonella* at different time points (2, 4 and 6 d post infection). DNA was extracted as previously described. Fungal burden was expressed as ng of fungal DNA / gram of larvae.

Statistical analysis

Statistical analyses were performed with GraphPad Prism, version 5 Project (GraphPad Software, San Diego, CA). The statistical significance of variances between fungal burdens was

calculated by using a nonparametric Mann-Whitney *t* test. A *p* value <0.01 was considered significant.

Kaplan-Meier survival curves were analyzed by using a log-rank (Mantel-Cox) test for significance. A *p* value <0.01 was considered significant.

Nucleotide sequence accession numbers

The full nucleotide sequences of the *cyp51A* genes used in this work appear in the GenBank nucleotide sequence database under Accession Nos. GU479991 for *A. lentulus cyp51A* and Accession Nos. AF338659 was the reference sequence used for *A. fumigatus*.

Results

Detection of *A. fumigatus* and *A. lentulus* by one step Multiplex Nested Real Time PCR

As accurate species identification could influence the infection outcome, a one-step diagnostic tool based on a multiplex nested PCR (MN-PCR) was optimized for differential detection of *A. fumigatus* and *A. lentulus*. Two sets of primers were designed for the first and second round of amplification including 2 degenerated outer primers, 2 specific inner primers and 2 Molecular Beacon probes labeled with FAM and HEX specific for *A. fumigatus* and *A. lentulus*, respectively. The design was based in a region of the *cyp51A* gene that contained a common intron of 71 bp. This region allowed the design of common primers for all the *Aspergilli* of the section *Fumigati* and specific probes for each species within the group (Fig. S1).

The detection limit of the designed PCR was calculated at 200 fg of DNA in 20 µl of PCR reaction mixture for both *A. fumigatus* and *A. lentulus*. The efficiency for both PCR amplifications was higher than 86% with coefficients (*r*²) of 0.99 (Fig. S2). The averages of coefficients of variation for all DNA concentrations were 3.4% for *A. fumigatus* and 2.7% for *A. lentulus*. Once the PCR conditions were optimized, the developed MN-PCR assay was validated on 40 clinical strains of *A. fumigatus* and *A. lentulus* with a specificity of 100%. Sequencing of all PCR amplified fragments confirmed the specificity. No signal was detected when 2 ng of DNA from other fungi (different species of *Aspergillus*, *Fusarium*, *Candida*, mucorales etc. .) and genomic DNA from human and mouse were also tested. In addition, no cross-reaction was observed between *A. fumigatus* and *A. lentulus*.

In order to validate the MN-PCR assay *in vivo*, first we used an experimental model of pulmonary aspergillosis using cyclophosphamide treated mice.²² Mice were infected with *A. fumigatus* (CM-237) or *A. lentulus* (CM-1290) and the infection was confirmed with positive cultures from lung tissues. A total of 8 mice inoculated with *A. fumigatus* had proven lung infection and positive PCR results from lung tissue. Similarly, PCR was positive in 13 of 14 lung samples (93%) from mice with proven infection with *A. lentulus*. The average of DNA concentration detected per µL in samples was 1.5×10^4 fg.

A second type of cortisone immunosuppressed murine model, closer to the cystic fibrosis patients, was performed.²³ In this model the PCR assay was able to detect 100% of samples from

mice with proven infection infected with *A. fumigatus* (10/10) or *A. lentulus* (10/10).

All together, the MN-PCR technique was positive in 41 of 42 samples (98%) and was able to distinguish both species in the 2 immunosuppressed mice models.

Differential pathogenesis of *A. lentulus* and *A. fumigatus* in *G. mellonella*

Prior to any assay *in vivo*, the growth rate and the antifungal susceptibility profile of *A. fumigatus* versus *A. lentulus* strains were compared *in vitro*. There were no differences in terms of colony size and radial growth between both species. As shown before,⁶ *A. lentulus* was resistant to VRC (MIC of 4 µg/L) while *A. fumigatus* was susceptible (MIC 0.5 µg/L) (Fig. S3). The virulence in the alternative host *Galleria mellonella* was determined by infecting the larva with an inoculum of each *Aspergillus* spp (1.5×10^5 cfu/larva). When *A. fumigatus* was used, 100% of infected larvae died between the 3rd and 4th day post infection. However, virulence of *A. lentulus* was slower and only 80% of larvae had died by day 10 post infection (Fig. 1A). The survival pattern of infection mimics that observed using the same inocula of *Aspergillus* spp in immunocompromised mice¹² (Fig. S4).

In order to explore the effect of *Aspergillus* infection on *G. mellonella* physiology, the infected larvae were fixed and paraffin-embedded sections were stained with PAS and evaluated for histological changes at different time points post infection (Fig. 1B). Histological analysis revealed differences between the *A. fumigatus* and *A. lentulus* infection pattern. Larvae showed branched invasive hyphal growth of *A. fumigatus* while *A. lentulus* was encapsulated by immune cells. Hemocytes with clearly visible nodule melanization were observed in nodules attached to organ structures and the fungus (Fig. 1B).

Voriconazole efficacy in an *in vivo* model of infection with *Aspergillus* spp using *G. mellonella*

The *G. mellonella* alternative model of infection was used to compare the efficacy of antifungal agents to treat *A. fumigatus* or *A. lentulus* infected larva. Groups of 20 larvae were infected with 1.5×10^5 spores per larvae and treated groups were inoculated with therapeutic doses of VRC (4 µg/larva equivalent to 10 mg/Kg/day) within 2 hours of infection. Virulence was reported as survival rate against time (Fig. 2A).

The results showed that at therapeutic doses of VRC, larvae infected with azole susceptible *A. fumigatus* (*akuB*^{KU80}) strain significantly improved survival in relation to the untreated group (*P* < 0.0002). In contrast, when *G. mellonella* were infected with the azole resistant *A. lentulus* strain (CM-1290), the percentage of survival showed no significant differences between this group and the respective untreated group (*p* = 0.7) (Fig. 2B).

To test VRC efficacy of *A. fumigatus* or *A. lentulus* *in vivo*, we used the developed MN-PCR to examine the fungal burden of *G. mellonella* infected with each *Aspergillus* strains. Time points were set at 2 and 4 d post infection. The analysis identified a significant decrease (*P* < 0.01) in the fungal burden retrieved from VRC treated larvae infected with *A. fumigatus* compared to *A.*

lentulus infected larvae, and in comparison with untreated animals (Fig. 2C) at both time points.

Histopathology analysis showed that when the larvae were infected with *A. fumigatus* and treated with VRC, the fungus was almost cleared with tissues appearing healthy. In contrast, *A. lentulus* CM-1290 strain persisted in the tissues even after 6 d of infection (Fig. 3).

Mixed infection model

A model of *A. fumigatus* and *A. lentulus* mixed fungal infection (1:1) in *G. mellonella* was used to evaluate the influence of intrinsically resistant species on the antifungal treatment outcome. Using the previously described model, larvae were infected with an equal amount of spores of both species (5×10^4 spores per larvae of each *Aspergillus* species). VRC response ($4 \mu\text{g/larva}$ equivalent to 10 mg/Kg) of the *G. mellonella* larvae infected with the mixture of *A. fumigatus* and *A. lentulus* was monitored by larvae survival rate and fungal burden using MN-PCR.

When the larvae were infected with a combination of both species, survival of infected larvae was intermediate to those of each single species infection respectively (Fig. 4A). In addition, *Aspergillus* spp mixed infected *G. mellonella* did not respond to therapeutic doses of VRC ($p = 0.08$) (Fig. 4B).

Analysis of fungal burden showed no differences of fungal DNA per larvae between 2 and 4 d for both *Aspergillus* species (Fig. 4C). When VRC was administered fungal burden dropped for *A. fumigatus* at both, 2 and 4 d post infection, compared to the untreated group ($P < 0.01$) (Fig. 4C and D). In the case of *A. lentulus* this decrease was statistically significant at 2 d ($p = 0.002$) but not at 4 d ($p = 0.35$) (Fig. 4C and D). The fungal burden was maintained at 6 d with no differences when it was compared to fungal burden of VRC treated larvae at 4 d post infection ($p = 0.44$) (Fig. 4D).

Discussion

Mixed infections are expected to occur in nature where interaction between co-infecting microorganisms will depend on the

host environment. The clinical relevance and the epidemiology of fungal mixed infections is relatively unknown but recent reports highlight the fact that these might be underestimated.²⁷ Mixed infections that include more than one fungal species are




Figure 1. (A) Survival rate of *G. mellonella* infected with *A. fumigatus* (CM-237) or *A. lentulus* (CM-1290) (10^5 spores/larvae). Control group (dotted line) represent survival of larvae inoculated with saline only. **(B)** Histopathology of *G. mellonella* infected with *A. fumigatus* and *A. lentulus*, at different times points of the infection (Day +2 and +4). 20 x magnification, PAS stained. Differences between the *A. fumigatus* and *A. lentulus* infection pattern: larvae showed branched invasive hyphal growth of *A. fumigatus* (steady arrows) while *A. lentulus* was encapsulated by immune cells (dash arrows).




Figure 2. (A) Killing rate comparison of *G. mellonella* infected with *A. fumigatus* with or without VRC treatment. (B) Killing rate comparison of *G. mellonella* infected with *A. lentulus* with or without VRC treatment. (C) Fungal burden determination in *G. mellonella* infected with *A. fumigatus* (AF) or *A. lentulus* (AL), untreated (NT) or treated with VRC. Statistical significance by unpaired t test of VRC treated vs. untreated data for each time point is marked as (* $P < 0.01$ or ** $P < 0.002$).

reported in superficial tissues, such as in onychomycosis infections, as well as in immunocompromised hosts.²⁸ Remarkably high death rates (75%) among bone marrow transplant patients infected with *Aspergillus* spp and among patients infected with *Aspergillus* spp. and *Candida* spp (100%) have been reported.²⁹ Also, a report of a mixed infection of the lung with *C. albicans* and *A. fumigatus* in a patient on prolonged steroid therapy was recently published.³⁰ Several case reports have described invasive aspergillosis caused by mixed infection with *A. flavus* and *A. fumigatus*³¹ or by cryptic *Aspergillus* species.³² These studies are concluding that mixed infections are very complex and they

could challenge current fungal diagnosis. Furthermore, they are often associated to lack of response to antifungal treatment and to bad outcome, and normally linked to high mortality rates. Among mixed infections cryptic species are especially important because fungal identification at species level is not straightforward. Additional methods are required, such as molecular identification, and this involve a longer time for diagnosis. In addition, the antifungal profile of *Aspergillus* species complex frequently shows high MICs to multiple antifungals.^{5,6}

The goal of our study was to develop and validate in tissue samples a PCR based assay able to distinguish between *A. fumigatus* (azole susceptible) and *A. lentulus* (azole resistant) as well as to standardize an alternative mixed infection model in order to correlate in vitro susceptibility profiles with antifungal drug response.

Aspergillus fumigatus accounts for most of the infections produced by filamentous fungi and it is usually susceptible to azole drugs, while *A. lentulus*, a species belonging to section *Fumigati*, has high MICs to multiple antifungals including VRC and AmB.⁶ A correct and early diagnosis leading to a prompt antifungal therapy is one essential step to improve clinical outcome. In this sense, molecular techniques have been proven to be very useful for the diagnosis of fungal infections, and most of them are based on the detection of the Internal transcriber Spacer (ITS) regions of the rDNA.³³ However, ITS sequences cannot be used to differentiate species within the *A. fumigatus* complex.³⁴ This is a great disadvantage as, until now, only single locus genes have been able to discriminate between those species. Among them, the more usual targets have been β -tubuline, calmodulin, and rodlet A genes.^{6,35} The use of single copy genes shows better discriminatory power but have the inconvenience of lack of sensitivity when clinical samples such as blood or BALs are used. In order to improve this, we developed a multiplex quantitative one-step nested PCR (MN-PCR) targeting the intron sequences of the azole target, 14- α sterol demethylase (*cyp51A*).

The developed MN-PCR is useful for the correct identification of *A. fumigatus* and *A. lentulus*. Moreover, it allows discrimination of *A. fumigatus* and closely related species and it can be implemented for the correct identification of other *Aspergillus* species in the section *Fumigati* in clinical specimens (under way in our laboratory). Also, the assay has been validated in cultured strains and in lung samples from 2 experimental mice models of invasive aspergillosis with excellent sensitivity (98%) and specificity (100%).

The *G. mellonella* model was used to explore *Aspergillus* spp fungal virulence and the in vivo correlation with in vitro antifungal susceptibility data. Results showed a high correlation in terms of survival rate between the murine and the wax moth model of aspergillosis¹² (Supplementary Fig. 4). Similarly to the murine model, *A. lentulus* was pathogenic in *G. mellonella*, although survival of infected larvae was prolonged compared to larvae infected with *A. fumigatus*. Those differences in the virulence pattern would suggest a more rapid or invasive growth characteristic of *A. fumigatus* in vivo.

Also, comparative analysis of tissue sections of *G. mellonella* infected with each *Aspergillus* spp showed a different pattern.

Larvae melanization occurred with both species at all time points, but recruitment of haemocytes differed. Branched invasive hyphal growth of *A. fumigatus* was observed in untreated larvae while the pattern of infection with *A. lentulus* was encapsulated hypha by immune cells producing nodules. This data suggests that *A. fumigatus* and *A. lentulus* might use different strategies to respond to host defenses. While *A. fumigatus* escapes from haemocytes, germinates and quickly develops in the host, *A. lentulus* is encapsulated by immune cells. No statistical differences were found in terms of haemocyte density between the 2 species in any of the time points, although it seems that there is a delay of the immune response by haemocytes against *A. lentulus* compared to *A. fumigatus* (data not shown). Changes in haemocyte density following microbial challenge have been previously observed³⁶ correlating high haemocyte concentration with longer survival rates.

Galleria mellonella presents certain benefits in comparison with other non-mammalian models of infection.¹⁴ Previous studies have documented that *G. mellonella* is a valid model to evaluate the microbial virulence and/or the efficacy of different antimicrobial agents in infections caused by different bacteria³⁷ and fungi, such as *C. neoformans*,^{38,39} *Candida* spp,^{40,41} *Histoplasma* spp.⁴² and *A. fumigatus*.²⁵ In addition, the *G. mellonella* model appears to be a promising approach to evaluate fitness of drug-resistant strains.⁴³

Since VRC is the first line antifungal used to treat aspergillosis, we also analyzed the *in vivo* response of *G. mellonella* infected with *A. fumigatus* or *A. lentulus* and treated with this antifungal. *G. mellonella* was a useful model in the evaluation of the efficacy of VRC at concentrations equivalent to the therapeutic doses used in humans. The results correlated very well with the antifungal susceptibility phenotype shown *in vitro*. While VRC was capable of improving the survival of larvae infected with azole susceptible *A. fumigatus*, this drug was ineffective for larvae infected with azole resistant strains (*A. lentulus*).

To further investigate the effect of antifungals during infection, we




Figure 3. Histopathology of *G. mellonella* infected with *A. fumigatus* and *A. lentulus* and treated with VRC, at different time points of the infection (Day +2, +4 and +6). 20 x magnification, PAS stained. Upper panel: when the larvae were infected with *A. fumigatus* and treated with VRC, the fungus was almost cleared with tissues appearing healthy. Lower panel: *A. lentulus* CM-1290 strain persisted in the tissues with an increase of fungal burden after 4 and 6 d post-infection (black arrows).

analyzed fungal burden of *Aspergillus* infected larvae by the MN-PCR described before. MN-PCR showed progressive increases in the *Aspergillus* burden during the time of infection at 2 and 4 d post infection, although it was not significant, when larvae were not treated with VRC. Antifungal treatment significantly reduced




Figure 4. (A) Survival rate of *G. mellonella* infected with a mixture of *A. fumigatus* (AF):*A. lentulus* (AL) (1:1) compared to single infections. (B) Comparative analysis of VRC treated and untreated larvae (This data is the same that was used for Fig. 4A). (C) Fungal burden determination in *G. mellonella* infected with a mixed inocula of both *A. fumigatus* and *A. lentulus*. (D) Fungal burden determination and VRC treatment efficacy in a mixed fungal infection. Statistical significance by unpaired t test of *A. fumigatus* versus *A. lentulus* at 6 d is marked as (***) $P < 0.003$.

A. fumigatus DNA per gram of larvae at 2 d of infection. Reduction of fungal burden at 4 d of infection was observed for larvae infected with *A. fumigatus* and *A. lentulus* although that decrease was more prominent for *A. fumigatus* than for *A. lentulus* ($P < 0.002$ and $P < 0.01$ respectively) (Fig. 2C). These results suggest that isolates with higher VRC MICs might show a poorer response to antifungal treatment in vivo.⁷

Following the same steps, we used the model of *G. mellonella* to evaluate the efficacy of VRC in the mixed infection model. A similar approach to evaluate a mixed infection of *Rhizopus oryzae* and *A. fumigatus* using corticosteroid-immunosuppressed mice has been used to explore if the exposure to antifungals could provoke a selection pressure for breakthrough mucormycosis during infection.⁴⁴ Results of survival analysis and fungal burden of mice infected with both species showed that VRC pre-exposure in vitro promotes breakthrough infection in vivo with *R. oryzae* and increases mortality due to *R. oryzae*.⁴⁴

In our model, the results show that at therapeutic doses VRC did not significantly improved larval survival when they were co-infected with equal amounts of *A. fumigatus* and *A. lentulus*. In addition, quantitative analysis of fungal burden at 6 d post infection demonstrated *A. lentulus* selection by VRC in the mixed infection. This suggests that in a mixed infection with *A. fumigatus* and *A. lentulus* the treatment with VRC may facilitate invasive growth of *A. lentulus*. The eventual domination of *A. lentulus* over *A. fumigatus* is consistent with concepts of antimicrobial selection, where suppression of more susceptible populations pre-sages the emergence of resistant pathogens with reduced fitness cost.⁴⁵ Similarly, with malaria it has been proposed that when sensitive and resistant parasites co-infect the same host individuals, drug use would further increase the relative fitness of drug-resistant clones by removing drug-sensitive competitors.⁴⁶

It may seem that there is a discrepancy between the decrease in fungal burden and the lack of response in survival of *G. mellonella* infected with *A. lentulus* in the single and the mixed infection. It has been described that *A. lentulus* VRC MICs range from 4 to 6 mg/L.⁶ Therefore, the reduction of fungal burden of *G.*

mellonella infected with *A. lentulus* and treated with VRC compared to the untreated ones might be explained because VRC is able to eliminate or to reduce fungal growth to some extent but not enough to improve survival of the *Galleria* at the VRC concentration that was tested. We cannot discard that *A. lentulus* would respond in vivo if higher concentrations of VRC are used.

Altogether, this data indicates that *G. mellonella* is a simple model that can also be used to evaluate competition and in vivo fitness in mixed infections by fungi. Moreover, we were able to simultaneously detect 2 species closely related such as *A. fumigatus* and *A. lentulus* by using real time PCR, showing a promising tool for clinical detection of *Aspergillus* section *Fumigati* in single or mixed infections. Given the differences in antifungal susceptibility between both species, antifungal pressure against *A. fumigatus* might be relevant for selective infection by *A. lentulus*. In conclusion, the presence of antifungal resistant species would likely complicate the management of fungal infections, thus representing a threat for patients under long-term azole treatment.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Gema del Rio for technical assistance.

Funding

EM was supported by Fondo de Investigación Sanitaria (FIS: PI12_02376). LA-F was funded by Fondo de Investigación Sanitaria with a Miguel Servet fellowship (FIS:CP11/00026).

Supplemental Material

Supplemental data for this article can be accessed on the publisher's website.

References

- Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-100; PMID:20218877; <http://dx.doi.org/10.1086/651263>.
- Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 2011; 66 Suppl 1: i5-14; PMID:21177404; <http://dx.doi.org/10.1093/jac/dkq437>.
- Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-11; PMID:20218876; <http://dx.doi.org/10.1086/651262>.
- Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. *Aspergillus lentulus* sp. nov., a new sibling species of *A. fumigatus*. Eukaryot Cell 2005; 4: 625-32; PMID:15755924; <http://dx.doi.org/10.1128/EC.4.3.625-632.2005>.
- Alastruey-Izquierdo A, Mellado E, Pelaez T, Peman J, Zapico S, Alvarez M, Rodriguez-Tudela JL, Cuenca-Estrella M; FILPOP Study Group. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 2013; 57: 3380-7; PMID:23669377; <http://dx.doi.org/10.1128/AAC.00383-13>.
- Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. *Aspergillus* section *Fumigati*: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother 2008; 52: 1244-51; PMID:18212093; <http://dx.doi.org/10.1128/AAC.00942-07>.
- Zbinden A, Imhof A, Wilhelm MJ, Ruschitzka F, Wild P, Bloembergen GV, Mueller NJ. Fatal outcome after heart transplantation caused by *Aspergillus lentulus*. Transpl Infect Dis 2012; 14: E60-E63; PMID:22988985; <http://dx.doi.org/10.1111/j.1399-3062.2012.00779.x>.
- Alhambra A, Catalan M, Moragues MD, Brena S, Ponton J, Montejo JC, del Palacio A. Isolation of *Aspergillus lentulus* in Spain from a critically ill patient with chronic obstructive pulmonary disease. Rev Iberoam Micol 2008; 25: 246-9; PMID:19071895; [http://dx.doi.org/10.1016/S1130-1406\(08\)70058-5](http://dx.doi.org/10.1016/S1130-1406(08)70058-5).
- Montenegro G, Sanchez PS, Jewtuchowicz VM, Pinoni MV, Relloso S, Temporitti E, Iovannitti CA, Mujica MT. Phenotypic and genotypic characterization of *Aspergillus lentulus* and *Aspergillus fumigatus* isolates in a patient with probable invasive aspergillosis. J Med Microbiol 2009; 58: 391-5; PMID:19208894; <http://dx.doi.org/10.1099/jmm.0.005942-0>.
- Symoens F, Haase G, Pihet M, Carrere J, Beguin H, Degand N, Mely L, Bouchara JP. Unusual *Aspergillus* species in patients with cystic fibrosis. Med Mycol 2010; 48 Suppl 1: S10-S16; PMID:21067321; <http://dx.doi.org/10.3109/13693786.2010.501345>.
- Balajee SA, Weaver M, Imhof A, Gribskov J, Marr KA. *Aspergillus fumigatus* variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother 2004; 48: 1197-203; PMID:15047520; <http://dx.doi.org/10.1128/AAC.48.4.1197-1203.2004>.
- Mellado E, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Role of *Aspergillus lentulus* 14- α sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrob Agents Chemother 2011; 55: 5459-68; PMID:21947395; <http://dx.doi.org/10.1128/AAC.05178-11>.

13. Desalermos A, Fuchs BB, Mylonakis E. Selecting an invertebrate model host for the study of fungal pathogenesis. *PLoS Pathog* 2012; 8: e1002451; PMID:22319439; <http://dx.doi.org/10.1371/journal.ppat.1002451>.
14. Fuchs BB, Mylonakis E. Using non-mammalian hosts to study fungal virulence and host defense. *Curr Opin Microbiol* 2006; 9: 346-51; PMID:16814595; <http://dx.doi.org/10.1016/j.mib.2006.06.004>.
15. Jacobsen ID. *Galleria mellonella* as a model host to study virulence of *Candida*. *Virulence* 2014; 5: 237-9; PMID:24384470; <http://dx.doi.org/10.4161/viru.27434>.
16. Vicentefranqueira R, Moreno MA, Leal F, Calera JA. The *zrfA* and *zrfB* genes of *Aspergillus fumigatus* encode the zinc transporter proteins of a zinc uptake system induced in an acid, zinc-depleted environment. *Eukaryot Cell* 2005; 4: 837-48; PMID:15879518; <http://dx.doi.org/10.1128/EC.4.5.837-848.2005>.
17. da Silva Ferreira ME, Kress MR, Savoldi M, Goldman MH, Hartl A, Heinekamp T, Brakhage AA, Goldman GH. The *akuB*(KU80) mutant deficient for nonhomologous end joining is a powerful tool for analyzing pathogenicity in *Aspergillus fumigatus*. *Eukaryot Cell* 2006; 5: 207-11; PMID:16400184; <http://dx.doi.org/10.1128/EC.5.1.207-211.2006>.
18. Tang CM, Cohen J, Krausz T, Van NS, Holden DW. The alkaline protease of *Aspergillus fumigatus* is not a virulence determinant in two murine models of invasive pulmonary aspergillosis. *Infect Immun* 1993; 61: 1650-6; PMID:8478053.
19. Cove DJ. The induction and repression of nitrate reductase in the fungus *Aspergillus nidulans*. *Biochim Biophys Acta* 1966; 113: 51-6; PMID:5940632; [http://dx.doi.org/10.1016/S0926-6593\(66\)80120-0](http://dx.doi.org/10.1016/S0926-6593(66)80120-0).
20. Tang CM, Cohen J, Holden DW. An *Aspergillus fumigatus* alkaline protease mutant constructed by gene disruption is deficient in extracellular elastase activity. *Mol Microbiol* 1992; 6: 1663-71; PMID:1495393; <http://dx.doi.org/10.1111/j.1365-2958.1992.tb00891.x>.
21. Tang X, Bartlett MS, Smith JW, Lee CH. A single-tube nested PCR for *Pneumocystis carinii* *f. sp. hominis*. *J Clin Microbiol* 1997; 35: 1597-9; PMID:9163492.
22. Mellado E, Garcia-Effron G, Buitrago MJ, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Targeted gene disruption of the 14- α sterol demethylase (*cyp51A*) in *Aspergillus fumigatus* and its role in azole drug susceptibility. *Antimicrob Agents Chemother* 2005; 49: 2536-8; PMID:15917566; <http://dx.doi.org/10.1128/AAC.49.6.2536-2538.2005>.
23. Amich J, Vicentefranqueira R, Mellado E, Ruiz-Carmuega A, Leal F, Calera JA. The *ZrfC* alkaline zinc transporter is required for *Aspergillus fumigatus* virulence and its growth in the presence of the Zn/Mn-chelating protein calprotectin. *Cell Microbiol* 2014; 16: 548-64; PMID:24245710; <http://dx.doi.org/10.1111/cmi.12238>.
24. Mesa-Arango AC, Forastiero A, Bernal-Martinez L, Cuenca-Estrella M, Mellado E, Zaragoza O. The non-mammalian host *Galleria mellonella* can be used to study the virulence of the fungal pathogen *Candida tropicalis* and the efficacy of antifungal drugs during infection by this pathogenic yeast. *Med Mycol* 2013; 51: 461-72; PMID:23170962; <http://dx.doi.org/10.3109/13693786.2012.737031>.
25. Slater JL, Gregson L, Denning DW, Warn PA. Pathogenicity of *Aspergillus fumigatus* mutants assessed in *Galleria mellonella* matches that in mice. *Med Mycol* 2011; 49 Suppl 1: S107-S113; PMID:20950221; <http://dx.doi.org/10.3109/13693786.2010.523852>.
26. Rueda C, Cuenca-Estrella M, Zaragoza O. Paradoxical growth of *Candida albicans* in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence. *Antimicrob Agents Chemother* 2014; 58: 1071-83; PMID:24295973; <http://dx.doi.org/10.1128/AAC.00946-13>.
27. Pelaez Garcia T, Gama B, Garcia-Gil V, Alcazar-Fuoli L, Escribano P, Guinea J, Muñoz P, Mellado E, Bouza E. Incidence of mixed invasive aspergillosis in a general hospital in Madrid: An underestimated entity? In 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 10-13 May 2014. Abstract P0005A.
28. David R.Soll. Mixed Mycotic Infections, In: Brogden KA GJ, ed. *Polymicrobial Diseases*. Washington (DC): ASM Press, 2002.
29. Meyers JD. Fungal infections in bone marrow transplant patients. *Semin Oncol* 1990; 17: 10-3; PMID:2353204.
30. S J, Vipparti H. Mixed fungal lung infection with *Aspergillus fumigatus* and *Candida albicans* in an immunocompromised patient: case report. *J Clin Diagn Res* 2014; 8: DD08-DD10; PMID:24959447.
31. Orzechowski XM, Pasqualotto AC, Uchoa Sales MP, Bittencourt SC, Peixoto Camargo JJ, Severo LC. Invasive pulmonary aspergillosis due to a mixed infection caused by *Aspergillus flavus* and *Aspergillus fumigatus*. *Rev Iberoam Micol* 2008; 25: 176-8; PMID:18785789; [http://dx.doi.org/10.1016/S1130-1406\(08\)70041-X](http://dx.doi.org/10.1016/S1130-1406(08)70041-X).
32. Pelaez T, Alvarez-Perez S, Mellado E, Serrano D, Valerio M, Blanco JL, Garcia ME, Muñoz P, Cuenca-Estrella M, Bouza E. Invasive aspergillosis caused by cryptic *Aspergillus* species: a report of two consecutive episodes in a patient with leukaemia. *J Med Microbiol* 2013; 62: 474-8; PMID:23161769; <http://dx.doi.org/10.1099/jmm.0.044867-0>.
33. Schoch CL, Seifert KA, Huhndorf S, Robert V, Spouge JL, Levesque CA, Chen W; Fungal Barcoding Consortium; Fungal Barcoding Consortium Author List. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. *Proc Natl Acad Sci U S A* 2012; 109: 6241-6; PMID:22454494; <http://dx.doi.org/10.1073/pnas.1117018109>.
34. Balajee SA, Houbroken J, Verweij PE, Hong SB, Yaghuchi T, Varga J, Samson RA. *Aspergillus* species identification in the clinical setting. *Stud Mycol* 2007; 59: 39-46; PMID:18490954; <http://dx.doi.org/10.3114/sim.2007.59.05>.
35. Serrano R, Gusmao L, Amorim A, Araujo R. Rapid identification of *Aspergillus fumigatus* within the section *Fumigati*. *BMC Microbiol* 2011; 11: 82; PMID:21510879; <http://dx.doi.org/10.1186/1471-2180-11-82>.
36. Bergin D, Brennan M, Kavanagh K. Fluctuations in haemocyte density and microbial load may be used as indicators of fungal pathogenicity in larvae of *Galleria mellonella*. *Microbes Infect* 2003; 5: 1389-95; PMID:14670452; <http://dx.doi.org/10.1016/j.micinf.2003.09.019>.
37. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Jr., Mylonakis E. *Galleria mellonella* as a model system to study *Acinetobacter baumannii* pathogenesis and therapeutics. *Antimicrob Agents Chemother* 2009; 53: 2605-9; PMID:19332683; <http://dx.doi.org/10.1128/AAC.01533-08>.
38. Garcia-Rodas R, Casadevall A, Rodriguez-Tudela JL, Cuenca-Estrella M, Zaragoza O. *Cryptococcus neoformans* capsular enlargement and cellular gigantism during *Galleria mellonella* infection. *PLoS One* 2011; 6: e24485; PMID:21915338; <http://dx.doi.org/10.1371/journal.pone.0024485>.
39. Mylonakis E, Moreno R, El Khoury JB, Idnurm A, Heitman J, Calderwood SB, Ausubel FM, Diener A. *Galleria mellonella* as a model system to study *Cryptococcus neoformans* pathogenesis. *Infect Immun* 2005; 73: 3842-50; PMID:15972469; <http://dx.doi.org/10.1128/IAI.73.7.3842-3850.2005>.
40. Brennan M, Thomas DY, Whiteway M, Kavanagh K. Correlation between virulence of *Candida albicans* mutants in mice and *Galleria mellonella* larvae. *FEMS Immunol Med Microbiol* 2002; 34: 153-7; PMID:12381467; <http://dx.doi.org/10.1111/j.1574-695X.2002.tb00617.x>.
41. Gago S, Garcia-Rodas R, Cuesta I, Mellado E, Alastruey-Izquierdo A. *Candida parapsilosis*, *Candida orthopsilosis*, and *Candida metapsilosis* virulence in the non-conventional host *Galleria mellonella*. *Virulence* 2014; 5: 278-85; PMID:24193303; <http://dx.doi.org/10.4161/viru.26973>.
42. Thomaz L, Garcia-Rodas R, Guimaraes AJ, Taborda CP, Zaragoza O, Nosanchuk JD. *Galleria mellonella* as a model host to study *Paracoccidioides lutzii* and *Histoplasma capsulatum*. *Virulence* 2013; 4: 139-46; PMID:23302787; <http://dx.doi.org/10.4161/viru.23047>.
43. Gomez-Lopez A, Forastiero A, Cendejas-Bueno E, Gregson L, Mellado E, Howard SJ, Livermore JL, Hope WW, Cuenca-Estrella M. An invertebrate model to evaluate virulence in *Aspergillus fumigatus*: the role of azole resistance. *Med Mycol* 2014; 52: 311-9; PMID:24577012; <http://dx.doi.org/10.1093/mmy/mtt022>.
44. Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of *Aspergillus fumigatus*-*Rhizopus oryzae* pulmonary infection. *Virulence* 2011; 2: 348-55; PMID:21788730; <http://dx.doi.org/10.4161/viru.2.4.17074>.
45. Anderson JB. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. *Nat Rev Microbiol* 2005; 3: 547-56; PMID:15953931; <http://dx.doi.org/10.1038/nrmicro1179>.
46. Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. *Proc Natl Acad Sci U S A* 2007; 104: 19914-9; PMID:18056635; <http://dx.doi.org/10.1073/pnas.0707766104>.